EG1

TargetMol
Product Code: TAR-T27246
Supplier: TargetMol
CodeSizePrice
TAR-T27246-1mg1mg£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27246-5mg5mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27246-1mL1 mL * 10 mM (in DMSO)£212.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27246-10mg10mg£252.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27246-25mg25mg£436.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27246-50mg50mg£610.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27246-100mg100mg£831.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27246-500mg500mg£1,589.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
EG1, a novel specific inhibitor of Pax2 transcription activation, targets the DNA binding domain and inhibits embryonic kidney development.
CAS:
693241-54-2
Formula:
C22H18N2O5
Molecular Weight:
390.395
Purity:
0.9773
SMILES:
COc1ccccc1C(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1C(O)=O

References

1. Smith CB, Phillips T, Smith TJ. Using the New ASCO Clinical Practice Guideline for Palliative Care Concurrent With Oncology Care Using the TEAM Approach. Am Soc Clin Oncol Educ Book. 2017;37:714-723. doi: 10.14694/EDBK_175474. PubMed PMID: 28561696. 2. Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, Daijo K, Nakamura-Inagaki Y, Morio K, Fujino H, Kan H, Uchida T, Masaki K, Kobayashi T, Nakahara T, Makokha GN, Zhang Y, Nagaoki Y, Miki D, Tsuge M, Hiramatsu A, Imamura M, Abe-Chayama H, Kawakami Y, Ochi H, Chayama K. Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. J Gastroenterol. 2017 May 29. doi: 10.1007/s00535-017-1352-z. [Epub ahead of print] PubMed PMID: 28555325. 3. Germain D. Toward the identification and the targeting of key players of the mitochondrial unfolded protein response (UPR(mt)) in cancer. J Bioenerg Biomembr. 2017 May 29. doi: 10.1007/s10863-017-9716-x. [Epub ahead of print] PubMed PMID: 28555290. 4. Molotkov A, Mazot P, Brewer JR, Cinalli RM, Soriano P. Distinct Requirements for FGFR1 and FGFR2 in Primitive Endoderm Development and Exit from Pluripotency. Dev Cell. 2017 May 23. pii: S1534-5807(17)30386-6. doi: 10.1016/j.devcel.2017.05.004. [Epub ahead of print] PubMed PMID: 28552557.